目的：研究欧必亭对原发性肝癌介入治疗所致恶心呕吐的预防作用。方法：１ ０００例原发性肝癌患者行介入治疗，６００例于介入治疗前动脉内注射欧必亭５ｍｇ，对照组４００例患者未用欧必亭等５－羟色胺（５－ＨＴ３）受体拮抗剂预防呕吐。１８０例患者设自身对照，即第一次介入治疗时未用欧必亭，第二次介入治疗时动脉内注射欧必亭５ｍｇ。结果：１ ０００例患者介入治疗后４５５例（４５．５％）发生恶心呕吐，其中，欧必亭及对照组分别为２３５例（３９．２％）及２２０例（５５．０％）（Ｐ＜ ０．０１）。介入治疗术中发生恶心呕吐７５例（７．５％），欧必亭及对照组分别为２５例（４．２％）及５０例（１２．５％）（Ｐ＜ ０．０１）。１ ０００例患者介入治疗后发生较严重的恶心呕吐９６例，欧必亭及对照组分别为３５例（５．８％）及６１例（１５．３％）（Ｐ＜ ０．０１）。１８０例自身对照的患者，欧必亭及对照组恶心呕吐的发生率分别为３５．６％（６４例）及５２．８％（９５例），两组相差显著（Ｐ＜ ０．０５）。结论：原发性肝癌介入治疗前动脉内注射欧必亭５ｍｇ可以有效地减少术中及术后恶心呕吐的发生率，减轻恶心呕吐的程度，且耐受性较好。 Objective: To study the preventive effect of oubiding on nausea and vomiting caused by interventional treatment of primary liver cancer. METHODS: One thousand patients with primary liver cancer underwent interventional therapy. 600 patients were given intramuscular injection of 5 mg of oxybiotin before interventional therapy. 400 patients in the control group were not treated with 5-HT3 receptor antagonists such as oxybiotin to prevent vomiting. One hundred and eighty patients had their own controls, that was, they did not use oxybutine during the first interventional treatment, and 5 mg of oxybidine was injected intra-arterially during the second intervention. RESULTS: Nausea and vomiting occurred in 455 patients (45.5%) after interventional treatment in 1 000 patients, of which 235 (39.2%) and 220 (55.0%) were in Obi-ting and control group, respectively (P<0). .01). Nausea and vomiting occurred in 75 patients (7.5%) during interventional surgery, in 25 patients (4.2%) and 50 patients (12.5%) in Obi-Ting and control groups (P < 0.01). Ninety-six patients with severe nausea and vomiting occurred after interventional treatment in 1 000 patients, and 35 patients (5.8%) and 61 patients (15.3%) in Obi-ting and control groups, respectively (P < 0.01). In 180 self-control patients, the incidence of nausea and vomiting was 35.6% (64 cases) and 52.8% (95 cases) in Oberthurning and control groups, respectively, with a significant difference between the two groups (P<0.05). CONCLUSION: Intraarterial injection of 5 mg of oxyblastine before interventional treatment of primary liver cancer can effectively reduce the incidence of nausea and vomiting during and after surgery, reduce the degree of nausea and vomiting, and is well tolerated.